相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia
R. M. Stone et al.
LEUKEMIA (2012)
Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
Thomas Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
Sabine Kayser et al.
BLOOD (2009)
Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
Ken-Hong Lim et al.
BLOOD (2009)
A Mechanism-Based Population Pharmacokinetic Model for Characterizing Time-Dependent Pharmacokinetics of Midostaurin and its Metabolites in Human Subjects
Ophelia Q. P. Yin et al.
CLINICAL PHARMACOKINETICS (2008)
Cytochrome P450 Induction by Rifampicin in Healthy Subjects: Determination Using the Karolinska Cocktail and the Endogenous CYP3A4 Marker 4β-Hydroxycholesterol
K. P. Kanebratt et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Dose- and time-dependent pharmacokinetics of midostaurin in patients with diabetes mellitus
Yanfeng Wang et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
4β-Hydroxycholesterol is a new endogenous CYP3A marker:: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians
Ulf Diczfalusy et al.
PHARMACOGENETICS AND GENOMICS (2008)
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
Mark Levis et al.
BLOOD (2006)
KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders:: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients
Andres C. Garcia-Montero et al.
BLOOD (2006)
Prediction of time-dependent CYP3A4 drug-drug interactions: Impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition
A Galetin et al.
DRUG METABOLISM AND DISPOSITION (2006)
Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria
P Valent et al.
LEUKEMIA RESEARCH (2003)
The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
TD Bjornsson et al.
DRUG METABOLISM AND DISPOSITION (2003)